Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100-letter

Cancer Research

Volumn 73, Issue 9, 2013, Pages 2926-

  End, David ^a   Molina, Arturo ^a   Todd, Mary ^b   Meyers, Michael L ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; CORTICOTROPIN; CYTOCHROME P450; CYTOCHROME P450 17A1; ENZALUTAMIDE; EPLERENONE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; POTASSIUM; PREDNISOLONE; PREDNISONE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); CORTICOTROPIN RELEASE; DOWN REGULATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG LABELING; DRUG RECEPTOR BINDING; ENZYME INHIBITION; GENE MUTATION; HUMAN; HYPERTENSION; HYPOKALEMIA; LETTER; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; WILD TYPE;

ANDROSTENOLS; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PREDNISOLONE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SPIRONOLACTONE;

EID: 84877767791     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2910     Document Type: Letter

References (5)

1. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, et al. Interactions of abiraterone, epeleronone and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012;72:2176-82.
2. Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cell lines. J Biol Chem 2012;287:3777-87.
3. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-71.
4. Zhao XY, Malloy PJ, Krishnan AV,Swami S, NavoneNM, Peehl DM,et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:703-6.
5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer.NEngl J Med 2011;364:1995-2005.